The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Could RO7851624, newly into clinical trials, be RG6735?
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
No sooner does one gammadelta-focused biotech die than another takes its place.
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
